Company Analysis
Sign in

Aardvark Therapeutics, Inc. (AARD)

Nasdaq: AARD · Pharmaceutical Preparations · San Diego, CA · filing with the SEC since 2019
Full chart Alerts Compare
Grade5.1
◀ Past 4.4● Present 5.5▶ Future 5.2
5 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
Revenue$5.1M+112.9%
Net income-$57.6M-179.7%
Earnings per share$-2.93+43.1%
Operating cash flow-$54.2M-199.5%
Cash$47.1M-23.7%
Debtn/a
Shareholders’ equity$107M+295.1%
Shares, diluted19.6M+391.1%
Return on equity-54.0%
The recordfrom its filings
Filings in 202642
Newest filingNov 13 · 10-Q
Annual reportMar 23, 2026
Quarterly reportNov 13, 2026
Next report due10-K by Mar 31
Insider sales, 12 months$400,000
Insider buys, 12 months$100,000
Patents granted7
Filer category<br>Emerging growth company
Trailing twelve months to Sep 2026Revenue $3.2MNet income -$72.8MCash from operations -$66.8Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
2425
As filed, in USD. Nothing here is a forecast.

News

Nov 13, 2026 · SEC EDGAR · Form 10-Q
Quarterly report
Open the filing on sec.gov
Nov 10, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Nov 10, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Nov 10, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Oct 23, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
Oct 22, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
Oct 8, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Oct 8, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton AARD · research, not advice